Glenn C. David's extensive experience in financial and commercial leadership roles, particularly in the animal health sector with companies like Zoetis Inc. and Pfizer Inc., positions him as a strong asset for Phibro. His background suggests he could implement strategies that enhance financial discipline and create value for shareholders, potentially leading to positive investor sentiment and a favorable impact on PAHC's stock price in the short term.